InvestorsHub Logo
Followers 12
Posts 628
Boards Moderated 0
Alias Born 08/03/2020

Re: BonnieMac post# 99332

Thursday, 04/15/2021 1:38:23 AM

Thursday, April 15, 2021 1:38:23 AM

Post# of 199220
I watched it again. Thanks for the link. I would think that Big Pharma could become interested in ITV-1 before the 1.5 year completion estimate based on the fact they said they could be interested in clone3 at/after animal trials.

I also wonder what happens with the covid mAbs once the patent is approved...and how long does this take? Could a company use them or add them to their already approved treatment with less testing or accelerated testing based on their connections or processes in place to speed this up because of covid.

Either way, I feel a lot will develop and happen between now and the next two years. They are projecting to create as much revenue as Gilead and Merck once they are up and running....though I imagine their plan is to partner, licence and make some of that revenue.

Itv 1 - HIV

2 patents
Clinically tested under EU standard
Cost interfered and not completed
80% drop in viral load etc…
Preparing to conduct new trials EMA
Partnership with EU businessmen
They will pay for the clinical trials
EU and asia distribution
FDA recognition could also happen after EMA validation order in a few months but not the focus because EMA is quicker
Clinical trials begin in 4 or 5 months….validation order first
Clinical trails could be finished in 1.5 years from now and ready for market

Clone 3 mAbs - HIV

Clone 3 has been tested in 5 labs around the world
Neutralized 95% of isolates it was tested against
First U of Strasbourg France
Then animal trials in California (Big Pharma suggested they would begin to be interested at this stage)
Then human trials
To market if successful

Covid mAbs

Have submitted patent applications for both mAbs and conserved sites discovered
Have started to produce the mAbs
Could be used by other companies in a “cocktail” treatment

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENZC News